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Structures of Falcipain-2 and Falcipain-3 Bound to Small Molecule Inhibitors: Implications for
Substrate Specificity‡
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Linda S. Brinen*,†
Department of Cellular and Molecular Pharmacology and Department of Pathology, UniVersity of California,
San Francisco, California 94158, and the Department of Medicine, San Francisco General Hospital, UniVersity of California,
San Francisco, California 94143
ReceiVed October 28, 2008
Falcipain-2 and falcipain-3 are critical hemoglobinases of Plasmodium falciparum, the most virulent human
malaria parasite. We have determined the 2.9 Å crystal structure of falcipain-2 in complex with the
epoxysuccinate E64 and the 2.5 Å crystal structure of falcipain-3 in complex with the aldehyde leupeptin.
These complexes represent the first crystal structures of plasmodial cysteine proteases with small molecule
inhibitors and the first reported crystal structure of falcipain-3. Our structural analyses indicate that the
relative shape and flexibility of the S2 pocket are affected by a number of discrete amino acid substitutions.
The cumulative effect of subtle differences, including those at “gatekeeper” positions, may explain the
observed kinetic differences between these two closely related enzymes.
Introduction
Approximately 300-500 million cases of malaria occur each
year, leading to over 1 million deaths, nearly all from Plasmo-
dium falciparum.1 Widespread drug resistance increasingly
limits the effectiveness of available therapies. New targets are
required for the development of novel classes of antimalarial
drugs.2 Trophozoites of P. falciparum hydrolyze hemoglobin
in an acidic food vacuole to generate free amino acids essential
for parasite survival.3,4 This process is blocked by the cysteine
protease inhibitors E64 and leupeptin, as evidenced by the
accumulation of undigested hemoglobin in the vacuole.5
The P. falciparum genome contains 33 open reading frames
predicted to encode cysteine proteases, including 4 cathepsin
L-like papain-family proteases collectively known as falcipains.
Falcipain-1 (FP1a) has an uncertain role; although the protease
is implicated in erythrocyte invasion, gene disruption has no
effect on the development of erythrocytic parasites.6,7 Disruption
of falcipain-2 (FP2) leads to a marked reduction in hemoglobin
hydrolysis by trophozoites, although this phenotype is transient;8
disruption of the nearly identical falcipain-2′ (FP2′) has no
apparent phenotype.9 Disruption of falcipain-3 (FP3) has so far
proved unsuccessful, and this result, taken together with the
ready replacement of the gene by a plasmid-encoded copy,
suggests an indispensable function for this protease.9
FP2 and FP3 share 66.7% sequence identity. This high level
of similarity and a preference for substrates with a hydrophobic
residue at the P2 position identifies these enzymes as cathepsin
L-like. FP2 and FP3 contribute more or less equally to the
digestion of hemoglobin in the food vacuole, with FP2 expressed
earlier in the parasite life cycle.10 Comparisons of FP2 and FP3
in the presence of smaller ligands show that FP3 is far less active
against peptide substrates10,11 and is usually less amenable to
inhibition by peptidyl-based small molecules. We report the 2.9
Å crystal structure of FP2 in complex with E64 and the 2.5 Å
crystal structure of FP3 in complex with leupeptin, providing
detailed analyses of the active sites in the presence of small
molecule inhibitors.
Results
Overall Structure. Cocrystallized FP2-E64 consists of
residues 1-241 of the mature enzyme. The C2221 asymmetric
unit contains four molecules. Superimposition of the two most
complete monomers (A and B) matches 235 R-carbons with
root-mean-square distances (rmsd) of 0.56 Å. Residues 1-16
and 185-198 are located in insertions novel to plasmodial
cysteine proteases and are more flexible than the rest of the
structure. These two regions are only partially built in some
monomers, and their exclusion matches 210 R-carbons with an
rmsd of 0.45 Å.
FP3-leupeptin crystals belong to spacegroup R32 with two
molecules of the mature enzyme, comprising residues 8-250,
in the asymmetric unit. The two copies of the complex
superimpose with an rmsd of 0.51 Å over 232 R-carbons. FP3
contains insertions equivalent to residues 1-16 and 185-198,
and their exclusion matches 210 R-carbons with an rmsd of 0.45
Å. Residues 195-203 exhibit a higher degree of flexibility when
compared to the surrounding structure. These residues are not
well resolved in monomer B of FP3-leupeptin and are therefore
not included in the model. Unless otherwise indicated, and for
the sake of simplicity, our structural analyses involve monomer
B from FP2 and monomer A from FP3, the best resolved
monomer from each complex.
The Dali server12 identifies cruzain, the major cysteine
protease of Trypanosoma cruzi, as the parasitic homologue with
the closest structural identity to both FP2 and FP3. All three
share the common and well-characterized structural features of
the two-domain papain-like fold. The core structure of the
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domains is essentially identical to that found in all previously
determined FP2 structures,13-15 with minor variations in the
insertions and loop regions. FP2 and FP3 share a high degree
of structural similarity, and superimposition, using the DaliLite
server,12 matches 236 R-carbons with an rmsd of 0.8Å and a
Z-score of 39.6 (Figure 1). The active site in each enzyme forms
an extended, accessible cleft and is detailed in later sections.
FP2 and FP3 Share Two Unique, Structurally
Equivalent Insertions. FP2 and FP3 share two unique insertions
that distinguish plasmodial cysteine proteases from all other
structurally characterized papain-family enzymes (Figure S1 in
Supporting Information). The first insertion is located at the
N-terminus of the mature enzyme and comprises residues 1-16
in FP2 and residues 1-25 in FP3. Residues 12-17 (monomer
C) and 12-19 (monomer D) in FP2 lacked sufficient electron
density to be included in the final models. Despite poor sequence
identity between FP2 and FP3 in this region, the loop-helix-loop
topology of the insertion (Figure 1) is well conserved and similar
to that described previously.13,15 The N-terminal insertion was
previously shown to mediate folding of mature FP2.4,16 Given
the conserved structure of the insertion, it seems likely that it
plays a similar role in FP3. Analogous to a similar interaction
in FP2,15 Tyr12 in FP3 provides a hydrogen-bonding anchor to
Glu147, helping to stabilize enzyme structure in this region. A
second possible anchor to Glu147, Lys20, is too distant to
participate in a hydrogen bonding interaction (4.1 Å in monomer
A, 4.4 Å in monomer B) and instead interacts with a sulfate
anion that is an artifact of crystallization.
The second insertion in FP2 and FP3 forms a 14-residue
-hairpin at the C-terminus. This portion of FP2 was implicated
in hemoglobin binding,17 and the secondary structure in this
region is well conserved between FP2 and FP3 (Figure 1). As
previously noted for FP2,13,15 this insertion has a tendency to
be flexible, and this is the case in our FP2-E64 and
FP3-leupeptin complexes. Accordingly, residues 189-193
(monomer A) and 182-198 (monomer D) in FP2 and 195-203
(monomer B) in FP3 lacked sufficient electron density to be
included in the final models.
Active Sites of FP2 and FP3. The active sites of both
enzymes are located in a cleft between the structurally distinct
domains of the papain-like fold. Leupeptin and E64 interact with
residues in the S1, S2, and S3 subsites of FP2 and FP3,
corresponding to the P1, P2, and P3 positions of the ligands.
The conserved catalytic residues of FP2 and FP3 (Gln36/45,
Cys42/51, His174/183, Asn204/213, respectively) are similarly
oriented with respect to the cocrystallized inhibitors. The active
site cysteine forms a covalent, irreversible hemithioketal with
the E64 epoxy carbon in the FP2-E64 complex and a covalent,
reversible hemithioacetal with the asymmetric carbonyl carbon
of leupeptin in the FP3-leupeptin complex (Figure 2).
As is commonly observed among inhibitors of papain-family
enzymes, the carboxyl group of E64 and carbonyl group of
leupeptin occupy the oxyanion hole formed by the conserved
catalytic residues (Figure S2 in Supporting Information). The
(4-guanidino) butane moiety in E64 and the arginal moiety in
leupeptin extend out into the solvent and are less ordered than
the rest of the inhibitor molecules. Accordingly, these moieties
are modeled at low occupancy in monomer B of both FP2 and
FP3.
The peptidyl small molecule inhibitors are tethered to the
main chains of FP2 and FP3 through a glycine residue that is
highly conserved in the S3 subsite of clan CA cysteine proteases
(Gly83 in FP2 and Gly92 in FP3). In each complex, this residue
forms hydrogen bonds with the O and N atoms of the inhibitor
backbone, similar to the pattern seen in -sheet formation in
protein secondary structure (parts A and B of Figure 3). In the
FP2 active site, Gln36, Ser41 (monomer C only), Cys42, Asn81
(monomer A only), and His174 are involved in the formation
of additional hydrogen bonds with E6418 (Table S1 in Support-
ing Information). In the FP3-leupeptin complex, Gln45, Cys51,
and Asn182 also act as hydrogen-bonding partners to the
inhibitor (Table S1 in Supporting Information). A series of
possible hydrophobic interactions are found between enzyme
and inhibitor, involving the nonpolar regions of Gly40, Tyr78,
Gly82, Leu84, Ser149, Leu172, Asn173, and Ala175 in FP2
and Tyr90, Gly91, Tyr93, Ile94, and Ser158 in FP3. Several
hydrogen bonds are formed between FP3 and leupeptin via
bridging water molecules; however, the interactions are not
conserved in both copies of the complex and are likely not ligand
dependent.
Discussion
The structures of FP2 and FP3 have been determined in
complex with the small molecule inhibitors E64 and leupeptin,
respectively. Both ligands display binding modes with their
partners similar to those found in other papain-family enzymes,
with these small molecule inhibitors largely targeting the S2
and S3 subsites. The P2 position in peptidyl ligands is the key
determinant of substrate specificity in clan CA cysteine pro-
teases.19 FP2 and FP3 have a clear preference for substrates
that contain a leucyl at this position (overall Leu > Phe >
Val).10,20 Both leupeptin and E64 contain a Leu at P2, and this
residue slots comfortably into the active site to be involved in
a number of hydrophobic interactions (Figure 3C).
FP2 and FP3 appear to perform similar functions in the
trophozoite food vacuole, and this is reflected in the high degree
of structural similarity shared by the two enzymes. Interestingly,
FP3 has been shown to be much less efficient at processing
peptide substrates and more difficult to inhibit with peptidyl-
based small molecules.10,11 The secondary structure that forms
Figure 1. Structures of FP2 and FP3: superimposition of FP2-E64
and FP3-leupeptin with FP2 colored blue and FP3 colored yellow.
Insertions are colored purple, and the N and C termini are labeled. All
structure figures were prepared in PyMOL.36
Figure 2. Chemical structures of E64 and leupeptin. The positions
that occupy the S1, S2, and S3 subsites (P1, P2, and P3, respectively)
are labeled. Enzyme and inhibitor groups involved during covalent bond
formation are highlighted in red.
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the active site is highly conserved between the two enzymes,
with no notable movements in the peptide backbone or loop
regions. However, facile superimposition of FP2 and FP3
highlights two important substitutions in the S2 subsite; Asp234
vs Glu243 and Leu84 vs Tyr93, respectively. The amino acid
at the Asp234/Glu243 position is nonconserved across the clan
CA enzymes. This position lines the base of the S2 subsite and
is known to be a key determinant of specificity. Both leupeptin
and E64 have a leucyl at P2 and are therefore unable to form
a charge-charge/hydrogen bonding interaction with an acidic
residue at the bottom of the S2 subsite. In the FP2-E64
complex, Asp234 is rotated away from the inhibitor, as is seen
in the complexes with chagasin (Leu at P214) and cystatin (no
P2 residue15). This residue is restricted from pointing out toward
the solvent through either a hydrogen bonding interaction with
the nearby Ser149 in the S2 subsite (monomer A) or interaction
with Asn86 through a bridging water molecule (monomer B).
Asp234 in monomers C and D possibly also form a stabilizing
hydrogen bond with Ser149; however, at 3.7 and 3.6 Å,
respectively, the distances are slightly too long for bond
formation.
Glu243 in the FP3-leupeptin complex also points away from
the inhibitor but, in contrast to the FP2-E64 complex, does
point out toward the solvent. The conformation of the side chain
is similar in both copies of the complex in the asymmetric unit
and is stabilized in both monomers through the formation of a
Figure 3. Active sites of FP2 and FP3. (A) FP2-E64 complex. Important residues in the active site are colored blue and labeled. E64 is least
flexible in monomer A (shown here) and colored gray. Interactions with the enzyme are in pink. (B) FP3-leupeptin complex. Important residues
in the active site are colored yellow and labeled. Leupeptin is colored gray, and interactions with the enzyme are in pink. (C) Surface representations
of FP2 (left) and FP3 (right) highlighting the contour of the S2 subsite and important residues therein. Ligands are depicted as in (A) and (B).
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direct hydrogen bond to Tyr245. This part of the S2 subsite is
more solvent exposed in monomer A, allowing additional
stabilizing interactions through bridging water molecules with
Ile94, Thr95, and the N-acetylcarbonyl of leupeptin. In com-
parison to Asp234 in FP2, the additional side chain carbon (and
thus rotatable bond) in Glu243 of FP3 increases the size of the
residue and the degree of side chain flexibility at this position.
In the FP3-leupeptin structure, the outcome of a larger, more
flexible residue at the bottom of the S2 subsite and the bulkier
Leu84 to Tyr93 substitution above is to narrow the wall of the
S2 subsite formed by Tyr93, Ile94, and Glu243 when compared
with the same region in FP2 (Leu84, Ile85, and Asp234)
(Figure 4).
A homology model of FP321 previously pointed to a role for
Tyr93 in restricting parts of the S2 subsite. The substitution of
Leu172 in FP2 to Pro181 in FP3 was also implicated and, in
combination with Tyr93, suggested to be directly responsible
for the narrowing of the S2 subsite. In the Fasciola hepatica
cathepsin L1, these two positions are referred to as “gatekeepers”
because they sit at the entrance to the S2 subsite.22 Tyr93, by
virtue of its size, may play a direct role in narrowing the S2
subsite. The role of Pro181, which has a substantially restrained
set of peptide φ/Ψ combinations compared to the other amino
acids, may be to reduce the conformational flexibility around
the entrance to the S2 subsite. The combination of a bulky Tyr
and a rigid Pro at “gatekeeper” positions serves to restrict the
types of ligands that are able to access the entrance to the active
site. As the major component of specificity is located at the S2
position of the enzyme, it is possible that amino acid changes
of this nature could restrict P2 accessibility, thereby influencing
catalytic efficiency and ligand recognition.
Overall, the complexes of FP2 and FP3 with E64 and
leupeptin show a simpler mode of binding and inhibition
compared to the previously determined crystal structures of FP2
with the macromolecular inhibitors chagasin and human
cystatin.14,15 The macromolecules adopt a tripartite mode of
binding to FP2, burying a much larger surface area than is seen
in either of our small molecule complexes. A wedge formed
by three protease binding loops (BC, DE, and FG) allows
chagasin to readily access both the prime and nonprime sites
of the active site. Cystatin is only able to access the solvent
exposed periphery of the nonprime sites and the majority of its
binding to FP2 occurs at the prime end of the active site.
An interesting feature of the FP2-chagasin interaction is the
highly mobile DE loop that, like E64, occupies the nonprime
sites. In chagasin, the DE loop residues Leu64 and Leu65
correspond to the P3 and P2 positions of the ligand, respectively,
and the peptide backbones occupy similar positions with respect
to the conserved glycine residues in the S3 subsite (Figure S3
in Supporting Information). Furthermore, mutational analyses
of ICP, a homologous macromolecular protease inhibitor from
Leishmania mexicana,23 highlight the importance of additional
residues in the DE loop. The triple mutants Gly69Pro, Gly71Pro,
Gly72Pro and Met67Asp, Val68Asp, Val70Asp abolished
inhibitory activity.
Similar to E64 and leupeptin, both chagasin and cystatin
inhibit FP2 and FP3 with nanomolar affinity. However, small
molecule inhibitors are much more attractive as potential leads
for the treatment of malaria. Unlike protein-based drugs, small
molecule therapeutics are generally much more bioavailable,
amenable to oral or topical administration, and vastly easier to
redesign. The structures described in this report should assist
ongoing efforts to develop falcipain inhibitors as new antima-
larial drugs.
Experimental Procedures
Expression and Purification of the Mature FP2 Enzyme. FP2
was expressed in E. coli strain M15(pREP4) harboring the hexa-
His-tagged pQ-35FP2 construct. Overexpression, refolding, and
purification were carried out according to published protocols.20
The pH of refolded FP2 was adjusted to 5.8, DTT was added to
a final concentration of 2.5 mM, and the solution was incubated at
room temperature for 40 min. Following activation, hemoglobin
and E64 (SIGMA) were added to a final concentration of 1 mM.
Unbound hemoglobin and E64 were removed using a 10 mL
Q-Sepharose column, and protein was eluted with a high salt buffer
(20 mM Bis-Tris, pH 6.5, 0.5 M NaCl). The kinetic activity of
purified FP2 was assayed as previously described17 and the protein
concentrated to approximately 7.4 mg/mL.
Expression and Purification of the Mature FP3 Enzyme. FP3
was expressed in E. coli strain M15(pREP4) harboring the hexa-
His-tagged FP3-pQE-30 construct. Overexpression, refolding, and
purification were carried out according to published protocols.10
The activity of FP3 was tested as for FP2 and was completely
abolished by the addition of leupeptin (SIGMA) to a final
concentration of 136 µM. Inhibited FP3 was purified using a 10
mL Q-sepharose column, and protein was eluted with high salt
buffer (20 mM Bis-Tris, pH 6.5, 0.5 M NaCl). Fractions that
contained FP3 were verified by SDS-PAGE, and buffer was
exchanged with 20 mM Bis-Tris, pH 6.5, and concentrated to
approximately 5 mg/mL.
Crystallization of FP2-E64 and FP3-Leupeptin Complexes.
Our crystallization of the FP2-E64 complex was serendipitous,
as initial trials were aimed at crystallizing FP2-E64 in complex
with its natural substrate, hemoglobin. Crystals of what were
believed to be the ternary complex were obtained using the sitting-
drop vapor diffusion method24 by equilibrating a mixture of 1 µL
of protein-inhibitor complex (7.4 mg/ml) and 1 µL of reservoir
solution (10% PEG 3350, 100 mM sodium nitrate, pH 6.0, 100
mM magnesium formate, 5% glycerol) against 500 µL of reservoir
solution at 22 °C.
FP3-leupeptin crystals were obtained using the sitting-drop
vapor diffusion method equilibrating 1 µL of protein-inhibitor
complex (3 mg/mL) and 1 µL of reservoir solution (1.3 M
ammonium sulfate, 50 mM sodium cacodylate, pH 6.5, 15 mM
magnesium acetate) against 1 mL of reservoir solution at 22 °C
Data Collection and Structure Determination. Crystals were
cryoprotected in mother liquor supplemented with 25% (FP2-E64)
Figure 4. S2 subsites of FP2 and FP3: surface representation of the
S2 subsites of FP2 and FP3. Colors are in accordance with Figure 3.
E64 is depicted in stick form.
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and 15% ethylene glycol (FP3-leupeptin), respectively. Samples
were then mounted in standard Hampton cryoloops, flash-cooled
in liquid nitrogen, and loaded into a Stanford automated mounting
system (SAM) sample cassette.25 Data were collected at the
Stanford Synchrotron Radiation Laboratory (SSRL) beamline 9-1,
Menlo Park, CA, on an ADSC Q-315 detector.
Diffraction data were collected from a single FP2-E64 crystal
as 0.5°, 35 s oscillations. FP2-E64 crystals belong to space group
C2221 (a ) 143.78 Å, b ) 167.81 Å, c ) 177.76 Å). Diffraction
data from a single FP3-leupeptin crystal were collected as 1°, 20 s
oscillations. FP3 crystals belong to space group R32 (a ) b )
154.57 Å, c ) 129.01 Å,  ) 120°). Reflections were indexed and
integrated using XDS26 for FP2-E64 and MOSFLM for
FP3-leupeptin.27 Data were scaled and merged with XSCALE for
FP2-E6426 and SCALA for the FP3-leupeptin complex.28 Be-
cause of the high redundancy of the data, we have included the
precision indicating merging R-factor, Rpim29 (calculated in SCA-
LA), in Table 1 as a more accurate description of the precision of
the averaged measurements. Structure factor amplitudes were
calculated using TRUNCATE.30
The structure of FP2-E64 was determined by molecular replace-
ment in PHASER31 using the FP2 component of the FP2-cystatin
complex (PDB 1YVB).15 Four independent monomers were located
in the asymmetric unit, yielding a solution with a log likelihood
gain (LLG) of 4982 and translation function Z-score of 50.2.
Following initial refinement in CNS,32 mFo - DFc SIGMAA-
weighted electron density maps confirmed that hemoglobin was
absent. However, the presence of E64 was clear and we were able
to position the small molecule inhibitor in the active site of all
four monomers. The model was refined over several rounds in CNS,
interspersed with manual adjustments in COOT.33 Refinement was
concluded in REFMAC5 using TLS parametrization.34 The model
shows good stereochemistry, as assessed by MOLPROBITY,35 and
is refined to a final Rfree and R-factor of 32.5% and 27.5%,
respectively. Structure statistics (PDB 3BPF) are summarized in
Table 1.
The structure of FP3 was determined by molecular replacement
in PHASER using one molecule of the FP2-E64 complex. Two
monomers were located in the asymmetric unit, yielding a solution
with a log likelihood gain (LLG) of 3661 and translation function
Z-score of 59.9. Refinement/rebuilding of the model and placement
of ligands followed the same protocol as the FP2-E64 structure.
The model shows good stereochemistry, as assessed by MOLPRO-
BITY, and is refined to a final Rfree and R-factor of 22.4% and
19.0%, respectively. Structure statistics (PDB 3BPM) are sum-
marized in Table 1.
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